Preclinical results of Alzheimer’s therapy project presented at AAIC 2017
17 July 2017 – At the Alzheimer's Association International Conference AAIC 2017 in London, UK, (16-19 July), Prof. Dr. Dieter Willbold presented the preclinical results from the ICS-6’s project to develop a novel causally effective drug candidate against Alzheimer’s disease. The yearly AAIC-meeting is the world's largest forum for the dementia research community.
His talk “Aβ Oligomer Eliminating D-Enantiomeric Peptides Enhance Cognition and Impede Neurodegeneration Even By Oral Application” was part of the AAIC- session “Preclinical: Basic Therapeutics – Targeting Amyloid or Tau” which he also co-chaired.
Spin-off projects Priavoid and attyloid presented at the AAIC-exhibition
In addition, both of the ICS-6’s spin-off projects in the field of Alzheimer’s disease were presented as part of the the AAIC company exhibition at Forschungszentrum Jülich’s booth. The therapy spin-off project Priavoid will focus on the further development of the drug candidate. The spin-off project attyloid will offer the proprietary sFIDA-technology for early diagnostics of neurodegenerative diseases.
Further Information